230 related articles for article (PubMed ID: 33895361)
1. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.
Lim SG; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lim K; Lee YM; Lee GH; Tan PS; Wai KL; Phyo WW; Khine HHTW; Lee C; Tay A; Chan E
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e228-e250. PubMed ID: 33895361
[TBL] [Abstract][Full Text] [Related]
2. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial.
Hu Q; Qi X; Yu Y; Gao Y; Zhang X; Wang Q; Zhang X; Zhuo Y; Li J; Zhang J; Chen L; Huang Y
Aliment Pharmacol Ther; 2022 Nov; 56(9):1394-1407. PubMed ID: 36128636
[TBL] [Abstract][Full Text] [Related]
7. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
9. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
10. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
11. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
Lampertico P; Brunetto MR; Craxì A; Gaeta GB; Rizzetto M; Rozzi A; Colombo M;
J Viral Hepat; 2019 Jan; 26(1):118-125. PubMed ID: 30187599
[TBL] [Abstract][Full Text] [Related]
12. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
14. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
15. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
16. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial.
Zhou Y; Yan R; Ru GQ; Yu LL; Yao J; Wang H
Hepatol Int; 2019 Jul; 13(4):422-430. PubMed ID: 31172416
[TBL] [Abstract][Full Text] [Related]
17. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
18. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
[TBL] [Abstract][Full Text] [Related]
19. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
[No Abstract] [Full Text] [Related]
20. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
Liang H; Wang C; Zhu PF; Zeng QL; Huang XB; Pan YF; Pan YJ; Hu QY; Luo X; Chen H; Yu ZJ; Lu FM; Lyu J
Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1297-1305. PubMed ID: 38253074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
